Indicators
Indicators
Value
Direction
MACD(12,26,9)
-0.022
Sell
RSI(14)
34.836
Neutral
STOCH(KDJ)(9,3,3)
23.238
Neutral
ATR(14)
0.121
Low Volatility
CCI(14)
-185.247
Sell
Williams %R
83.795
Oversold
TRIX(12,20)
-1.056
Sell
StochRSI(14)
66.604
Buy
Biodexa Pharmaceuticals PLC
BDRXView Detailed Chart
0.922USD
+0.056+6.42%
Close 06/23, 16:00（ET）Quotes delayed by 15 min
6.17BMarket Cap
--P/E TTM
Intraday
1m
30m
1h
D
W
M
D
Today
+6.42%
5 Days
-13.82%
1 Month
-33.66%
6 Months
-76.89%
Year to Date
-77.23%
1 Year
-96.52%
View Detailed Chart
Agency Rating
Analyst Rating
Based on
1
analysts
STRONG BUY
Current Rating
18.000
Target Price
1977.32%
Upside Space
Strong Buy
Buy
Hold
Sell
Strong Sell
Peer Comparison
557
Total
5
Median
6
Average
Company name
Ratings
Analysts
Biodexa Pharmaceuticals PLC
BDRX
1
CRISPR Therapeutics AG
CRSP
28
Regeneron Pharmaceuticals Inc
REGN
28
Intellia Therapeutics Inc
NTLA
28
Exact Sciences Corp
EXAS
28
Ionis Pharmaceuticals Inc
IONS
26
1
2
3
...
112
Indicators
The Indicators feature provides value and direction analysis for various instruments under a selection of technical indicators, together with a technical summary.
This feature includes nine of the commonly used technical indicators: MACD, RSI, KDJ, StochRSI, ATR, CCI, WR, TRIX and MA. You may also adjust the timeframe depending on your needs.
Please note that technical analysis is only part of investment reference, and there is no absolute standard for using numerical values to assess direction. The results are for reference only, and we are not responsible for the accuracy of the indicator calculations and summaries.
Sell
Moving Average
Indicators
Value
Direction
MA5
0.961
Sell
MA10
1.047
Sell
MA20
1.099
Sell
MA50
1.293
Sell
MA100
2.143
Sell
MA200
3.995
Sell
News
More news coming soon, stay tuned...
Company
Biodexa Pharmaceuticals PLC is a United Kingdom-based clinical-stage biopharmaceutical company. The Company is developing a pipeline of products for the treatment of diseases with unmet medical needs. Its technologies include Biodexa Pharmaceuticals Q-Sphera, MidaCore and MidaSolve. The Q-Sphera technology focuses on long-acting injectables using proprietary three-dimensional (3D) printing technology that encapsulates medicines into bioresorbable polymer microspheres with precision characteristics. The MidaCore technology platform uses ultra-small gold nanoparticle (GNP) drug conjugates. The MidaSolve Nano Inclusion technology solubilizes molecules that have minimal solubility biological potential of Hydrogen (pH), extending available routes of administration, including direct-to-tumor delivery. Its pipeline includes MTX110, MTD201, MTD211 (Schizophrenia, MDD), MTX223, and MTD217.
Ticker SymbolBDRX
CompanyBiodexa Pharmaceuticals PLC
CEOMr. Stephen A. Stamp
Websitehttps://www.biodexapharma.com/
Related Instruments
+2.89%
+0.43%
-0.26%
+0.32%
+4.22%
-3.30%
+2.67%
-0.83%
+7.43%
+0.56%
-3.89%
-0.63%
-0.09%
-0.89%
-0.91%
-0.23%
-5.66%
+0.16%
-1.18%
+0.96%
